CN102369436B - 用于检测jc多瘤病毒的方法 - Google Patents

用于检测jc多瘤病毒的方法 Download PDF

Info

Publication number
CN102369436B
CN102369436B CN201080014394.6A CN201080014394A CN102369436B CN 102369436 B CN102369436 B CN 102369436B CN 201080014394 A CN201080014394 A CN 201080014394A CN 102369436 B CN102369436 B CN 102369436B
Authority
CN
China
Prior art keywords
jcv
pml
subject
variant
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080014394.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102369436A (zh
Inventor
利奥尼德·戈雷利克
阿列克谢·卢戈夫斯柯伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biological Gene Ma Co
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42542341&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102369436(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN102369436A publication Critical patent/CN102369436A/zh
Application granted granted Critical
Publication of CN102369436B publication Critical patent/CN102369436B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
CN201080014394.6A 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法 Active CN102369436B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15031009P 2009-02-05 2009-02-05
US61/150,310 2009-02-05
PCT/US2010/000342 WO2010090757A1 (en) 2009-02-05 2010-02-05 Methods for the detection of jc polyoma virus

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201410478514.8A Division CN104316696A (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法

Publications (2)

Publication Number Publication Date
CN102369436A CN102369436A (zh) 2012-03-07
CN102369436B true CN102369436B (zh) 2014-10-22

Family

ID=42542341

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201080014394.6A Active CN102369436B (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法
CN201410478514.8A Pending CN104316696A (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201410478514.8A Pending CN104316696A (zh) 2009-02-05 2010-02-05 用于检测jc多瘤病毒的方法

Country Status (11)

Country Link
US (2) US20130101985A9 (https=)
EP (1) EP2394163B1 (https=)
JP (1) JP2012517017A (https=)
CN (2) CN102369436B (https=)
AU (1) AU2010210979B2 (https=)
BR (1) BRPI1016273A2 (https=)
CA (1) CA2751364C (https=)
ES (1) ES2842425T3 (https=)
NZ (1) NZ594973A (https=)
SG (2) SG173201A1 (https=)
WO (1) WO2010090757A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207141A1 (en) 2006-02-28 2007-09-06 Ivan Lieberburg Methods of treating inflammatory and autoimmune diseases with natalizumab
MX2008011176A (es) 2006-03-03 2008-09-10 Elan Pharm Inc Metodos para tratar padecimientos inflamatorios y autoinmunes con natalizumab.
CN102369436B (zh) 2009-02-05 2014-10-22 生物基因Idecma公司 用于检测jc多瘤病毒的方法
CN102906278A (zh) 2010-01-11 2013-01-30 比奥根艾迪克Ma公司 用于jc病毒抗体的测定
US11287423B2 (en) 2010-01-11 2022-03-29 Biogen Ma Inc. Assay for JC virus antibodies
DK2715352T3 (da) 2011-05-31 2019-05-20 Biogen Ma Inc Fremgangsmåde til vurdering af risiko for pml
DK2734544T3 (da) 2011-07-18 2021-03-15 Us Health Fremgangsmåder og sammensætninger til hæmning af polyomavirus-associeret patologi
EP2548567A1 (en) 2011-07-22 2013-01-23 Universitätsklinikum Hamburg-Eppendorf Polyoma virus JC peptides and proteins in vaccination and diagnostic applications
EP2636746A1 (en) * 2012-03-06 2013-09-11 Life Science Inkubator A novel drug delivery system based on JCV-VLP
WO2013142300A2 (en) * 2012-03-20 2013-09-26 Biogen Idec Ma Inc. Jcv neutralizing antibodies
ES2731757T3 (es) 2012-03-20 2019-11-18 Biogen Ma Inc Anticuerpos neutralizantes de JCV
WO2013192100A1 (en) 2012-06-18 2013-12-27 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods and compositions for detecting jc virus
CN104936980B (zh) * 2012-12-31 2019-06-07 生物控股有限公司 用于治疗和预防多瘤病毒相关的疾病的重组人抗体
SI2774991T1 (en) * 2013-03-06 2018-04-30 Life Science Inkubator Betriebs Gmbh & Co. Kg A system for supplying a medicament for use in the treatment or diagnosis of neurological disorders
EP2971119A4 (en) * 2013-03-15 2016-11-02 Biogen Ma Inc MELT ANALYSIS ASSAY HIGHLY RESOLVED TO DETECT VIRAL DNA
WO2014193804A1 (en) 2013-05-28 2014-12-04 Biogen Idec Ma Inc. Method of assessing risk of pml
WO2015095770A1 (en) 2013-12-20 2015-06-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogenic jc polyomavirus compositions and methods of use
US20200197544A1 (en) * 2017-04-26 2020-06-25 Biogen Ma Inc. Jcv imaging methods and compositions
CN112442553A (zh) * 2020-10-27 2021-03-05 深圳市罗湖区人民医院 一种用于JCPyV检测与分型的试剂盒及方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3767755B2 (ja) * 1995-06-23 2006-04-19 エーザイ株式会社 抗ｊｃウイルス抗体
DE19543553B4 (de) * 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
IL125517A0 (en) 1996-01-26 1999-03-12 Univ California Polymeric film assay and method for direct colorimetric detection of analytes
DE10131145B4 (de) 2001-06-28 2005-07-14 Innovent E.V. Zusammensetzung zum zellspezifischen Transfer von Wirkstoffen
JP4840792B2 (ja) 2001-11-22 2011-12-21 独立行政法人科学技術振興機構 ＪＣウイルスａｇｎｏを対象としたＰＭＬの治療
US20080131928A1 (en) 2004-07-01 2008-06-05 Hiroshi Handa Viral Particle-Like Construct and Method of Forming the Same Under Physiological Conditions
JP4757103B2 (ja) 2005-06-13 2011-08-24 学校法人関西文理総合学園 試料中のウイルスを検出する方法およびシステム
US7468186B2 (en) 2005-07-22 2008-12-23 City Of Hope Polyomavirus cellular epitopes and uses therefor
US20070134652A1 (en) 2005-11-09 2007-06-14 Primera Biosystems, Inc. Multiplexed quantitative detection of pathogens
US7769230B2 (en) * 2006-11-30 2010-08-03 Eastman Kodak Company Producing low resolution images
WO2008077511A1 (en) 2006-12-22 2008-07-03 Karolinska Institutet Innovations Ab Human polyomavirus and methods of diagnosis and treatment
JP2008249433A (ja) 2007-03-29 2008-10-16 Kansai Bunri Sogo Gakuen 被験物質に対するプローブの結合親和性を測定する方法及びその利用
US20110118340A1 (en) 2008-02-08 2011-05-19 Muthiah Manoharan Delivery of rnai constructs to oligodendrocytes
CN102369436B (zh) 2009-02-05 2014-10-22 生物基因Idecma公司 用于检测jc多瘤病毒的方法
KR20140057296A (ko) 2011-07-29 2014-05-12 바이오겐 아이덱 엠에이 인코포레이티드 Jc 바이러스 dna의 검출 분석
AR095089A1 (es) 2013-01-30 2015-09-30 Biogen Idec Inc Ensayo de detección de adn de virus jc

Also Published As

Publication number Publication date
US20130101985A9 (en) 2013-04-25
WO2010090757A1 (en) 2010-08-12
EP2394163B1 (en) 2020-08-19
US9696307B2 (en) 2017-07-04
EP2394163A4 (en) 2012-08-01
CA2751364A1 (en) 2010-08-12
SG173201A1 (en) 2011-08-29
CN104316696A (zh) 2015-01-28
EP2394163A1 (en) 2011-12-14
AU2010210979A1 (en) 2011-09-22
US20150219651A1 (en) 2015-08-06
NZ594973A (en) 2012-05-25
SG2014009120A (en) 2014-03-28
CA2751364C (en) 2017-06-20
US20120258443A1 (en) 2012-10-11
BRPI1016273A2 (pt) 2020-12-01
CN102369436A (zh) 2012-03-07
JP2012517017A (ja) 2012-07-26
ES2842425T3 (es) 2021-07-14
AU2010210979B2 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
CN102369436B (zh) 用于检测jc多瘤病毒的方法
Zhang et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections
Wang et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants
Walls et al. Unexpected receptor functional mimicry elucidates activation of coronavirus fusion
Javanmardi et al. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
Shang et al. Paired immunoglobulin-like receptor B is an entry receptor for mammalian orthoreovirus
Shang et al. NRP1 is a receptor for mammalian orthoreovirus engaged by distinct capsid subunits
Li et al. Structural basis of a two-antibody cocktail exhibiting highly potent and broadly neutralizing activities against SARS-CoV-2 variants including diverse Omicron sublineages
Hattori et al. The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition
Wang et al. Conserved neutralizing epitopes on the N-terminal domain of variant SARS-CoV-2 spike proteins
Geng et al. Lys417 acts as a molecular switch that regulates the conformation of SARS-CoV-2 spike protein
Wang et al. Longitudinal and proteome-wide analyses of antibodies in COVID-19 patients reveal features of the humoral immune response to SARS-CoV-2
Su et al. A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif
Byrnes et al. A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding
Mayberry et al. JC polyomavirus attachment and entry: potential sites for PML therapeutics
Xie et al. Orphan broadly RBD-binding antibodies annotate three remaining conserved RBD epitopes along SARS-CoV-2 evolution
WO2015095770A1 (en) Immunogenic jc polyomavirus compositions and methods of use
US11635434B2 (en) Betaretrovirus epitopes and related methods of use
Trang et al. BK polyomavirus: a review of the virology, pathogenesis, clinical and laboratory features, and treatment
Lechuga et al. Humoral response to dengue virus infections potentiates antibody-dependent enhancement of SARS-CoV-2
Malhotra Targeting epitope-specific T cells and modelling protein hypercitrullination in rheumatoid arthritis
Sandel Autoimmunity in Cardiomyopathy: From Myocarditis to Heart Failure
US20220042993A1 (en) Betaretrovirus epitopes and related methods of use
Dakroub The impact of pre-graft serology on the risk of BKPyV infection reactivation post-renal transplantation
Wang et al. Molecular blueprints of the Langya virus attachment and fusion glycoproteins

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: BIOGEN MA INC.

Free format text: FORMER NAME: BIOGEN IDEC MA LTD.

CP01 Change in the name or title of a patent holder

Address after: Massachusetts, USA

Patentee after: Biological gene MA company

Address before: Massachusetts, USA

Patentee before: Bio gene IDEC MA